{"id":701677,"date":"2022-10-27T07:56:27","date_gmt":"2022-10-27T11:56:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/"},"modified":"2022-10-27T07:56:27","modified_gmt":"2022-10-27T11:56:27","slug":"bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/","title":{"rendered":"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW HAVEN, Conn., Oct.  27, 2022  (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company\u2019s financial results and to provide a general business update.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"vertical-align: middle\">\n            <strong>Conference Call &amp; Webcast Details<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: middle\">\n            <strong>Date\/Time:<\/strong><br \/>\n            <br \/>\n            <strong>Domestic:<\/strong><br \/>\n            <br \/>\n            <strong>International:<\/strong>\n          <\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%;vertical-align: middle\">Thursday, November 10, 2022 at 8:30 AM Eastern Time<br \/>877-407-5795 <br \/>201-689-8722<\/td>\n<\/tr>\n<\/table>\n<p>The webcast and the accompanying materials will be accessible* under &#8220;News\/Events&#8221; on the Investors &amp; Media page of the Company&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a2n7ppytjpFU2lujesCsGoxYKN0ZDHE3YBqTkp5r2cMPMUmP7XjqJt9joW6EZEPKAETH6wO1drBxi8hpNu6IRnUSXTRcdlchDkXH7JEzRdy9BSdIiOoojMz2oxs25zSrNGi7N-LZc6B0p5hd9XOMXA0iXtZ_ybu8Ip4LMf7W9Xz9Gx61QAOiVH0US097RYUpWmXb3djZph2DLiv7Z2CQov5Nr5ttLdgq8Mbh5X6ZQJRtz4hmsbCkL2uO71t1CdO8AZdYnsM08vzXgiWZR_jqpNLSZuYQuYVX5p-qH4cscwo=\" rel=\"nofollow noopener\" target=\"_blank\">www.bioxceltherapeutics.com<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"vertical-align: middle\">\n            <strong>Replay<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: middle\">\n            <strong>Domestic:<\/strong><br \/>\n            <br \/>\n            <strong>International:\u00a0<\/strong><br \/>\n            <br \/>\n            <strong>Conference ID:<\/strong>\n          <\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%;vertical-align: middle\">877-660-6853<br \/>201-612-7415<br \/>13731851<\/td>\n<\/tr>\n<\/table>\n<p>*Replay available through February 10, 2023.<\/p>\n<p>\n        <strong>About BioXcel Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company\u2019s drug re-innovation approach leverages existing approved drugs and\/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company\u2019s commercial product, IGALMI\u2122 (developed as BXCL501), is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fRuf58vVRZgzfgSnQ76ELZCQeZ5vyxQSujCiF2-eaZS0Ky6pB4eVtWeWX3UM5mRjvbP-rCwZHj3q3Zvl8OQumH2chbWmo9Egwfz03ReodV0XrIOuRhaZI89EjZNYb5IRGgbr1OiUF6Z4jmCrLPvkuxO1mXk7ejoeUOsjqpGlqBxQOH7X2NO0dtspCR3_b5lp_lnWh5xPZweQNOQ1Z8lgp_NVYcvJ31v3HkcMBdFeIyss2i2GfZWbXYRhOAdRAkHV\" rel=\"nofollow noopener\" target=\"_blank\">www.IGALMIhcp.com<\/a>\u00a0and also see the IGALMI full\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r32FWFj4WHWJbZJiKia65pgzUUMbPcIZWkdCNBLX3XmcTdQYaAg2CL9qhdMCmizTBADWPh6x5Y2BWr_8vSnP8ej176b2RPWzz_zvhYIqCKAjx3mKDjYC9eUT2LqZyPyXX6ubsxDg5DCdgzAmw5YZhGJ7_ofMD6zHY9FQjEnufC3RAxgnggfxYm54PtVkHuML1ED-yYMIVdPUCUFAK0EkrQmzXUMBAQLBWbiZGmOONr9WjkwSPRoh7o0KN7qDYfnTlb3EuKHUS2PfAxaAkAj5fd2pxDH8A1KzRXeFcMCiL-M=\" rel=\"nofollow noopener\" target=\"_blank\">Prescribing Information<\/a>.\u00a0 BXCL501 is under evaluation for acute treatment of agitation associated with probable Alzheimer\u2019s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NdWUTQ1-Bfi8OPXxpTNIwPv6LaVl5zK3aC5bMxZnkOZUcOyjH443AeTT-ePXMx1-460ibWG4p66_-FvU_Vr6JJ5St-xJayAagzLhK9NzGGXss7_IbtdUlY90BGx1FClEzBBS3ZUTP0v8_W95PuT4ra06ku7XkCid5VH_Z1oMJ6RtYPifqQoS9obDvVzlomPDBH8hJ-ju8KhIXzFmIFISYNG8SiUdZOIxvXbUTMnpuEUgZnqPsgmVmurkZBHGsM_YDWWCocyT1Wm437SStcE0PQsGHoKXiGxDfX0QjeA4Rtg=\" rel=\"nofollow noopener\" target=\"_blank\">bioxceltherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release includes \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the date and time of the Company\u2019s third quarter 2022 financial results call. When used herein, words including \u201canticipate,\u201d \u201cwill,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201ccontinue,\u201d \u201cintend,\u201d \u201cdesigned,\u201d \u201cgoal\u201d and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company\u2019s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption \u201cRisk Factors\u201d in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC\u2019s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p>Contact Information<\/p>\n<p>\n        <u>Corporate<\/u>\n      <\/p>\n<p>BioXcel Therapeutics<br \/>Erik Kopp<br \/>1.203.494.7062<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=quhAr6Ztt7RYjxR5kgSk5fcoSZ7oRtdwnIcYh7W__mUjJ2hLGbsZYU6T2AfU2ivWja34waCZMhtMSgUgIC_JGa9LYp5uxXTt8-Plo1-InAxQZG_REPVhPhzobWcWrmgM\" rel=\"nofollow noopener\" target=\"_blank\">ekopp@bioxceltherapeutics.com<\/a>\u00a0<\/p>\n<p>\n        <u>Investor Relations<\/u>\n      <\/p>\n<p>BioXcel Therapeutics<br \/>Brennan Doyle<br \/>1.475.355.8462<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lxPnWZtyGDMyKDFcq9mWf1c7Mn4Co6ICuZUb1-bckD_AVxMMMXbS3bZ-GiYifp7zE8Pcz-P76O8I8libHijWQbDJ20AbGkpHgncXy-LGV9RSjHMLalA5_86PturtzDIW\" rel=\"nofollow noopener\" target=\"_blank\">bdoyle@bioxceltherapeutics.com<\/a>\u00a0<\/p>\n<p>\n        <u>Media<\/u>\n      <\/p>\n<p>FTI Consulting<br \/>Helen O\u2019Gorman<br \/>1.718.408.0800<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uyl85VOvHcRQQ68-mh2FHykWnvt2pEUdjTe564N7EJRzHOub2paW2shjdpF-k3kWg2OTssSfQDKbHC-VKGOgKIHfvjQSrZ4H2dhBt0vi0B6XLuAsmjA2WRUygi2KBYWL\" rel=\"nofollow noopener\" target=\"_blank\">helen.ogorman@fticonsulting.com<\/a>\u00a0<\/p>\n<p>Source: BioXcel Therapeutics, Inc.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjhkNjEwOWQtMThhNi00NWE1LTk1YmItMGQ5MzIzNTQ0YTExLTEyMDQ1MTA=\/tiny\/BioXcel-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company\u2019s financial results and to provide a general business update. Conference Call &amp; Webcast Details Date\/Time: Domestic: International: Thursday, November 10, 2022 at 8:30 AM Eastern Time877-407-5795 201-689-8722 The webcast and the accompanying materials will be accessible* under &#8220;News\/Events&#8221; on the Investors &amp; Media page of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701677","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company\u2019s financial results and to provide a general business update. Conference Call &amp; Webcast Details Date\/Time: Domestic: International: Thursday, November 10, 2022 at 8:30 AM Eastern Time877-407-5795 201-689-8722 The webcast and the accompanying materials will be accessible* under &#8220;News\/Events&#8221; on the Investors &amp; Media page of the &hellip; Continue reading &quot;BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T11:56:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022\",\"datePublished\":\"2022-10-27T11:56:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/\"},\"wordCount\":688,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/\",\"name\":\"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=\",\"datePublished\":\"2022-10-27T11:56:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/","og_locale":"en_US","og_type":"article","og_title":"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022 - Market Newsdesk","og_description":"NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics\u2019 management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company\u2019s financial results and to provide a general business update. Conference Call &amp; Webcast Details Date\/Time: Domestic: International: Thursday, November 10, 2022 at 8:30 AM Eastern Time877-407-5795 201-689-8722 The webcast and the accompanying materials will be accessible* under &#8220;News\/Events&#8221; on the Investors &amp; Media page of the &hellip; Continue reading \"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T11:56:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022","datePublished":"2022-10-27T11:56:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/"},"wordCount":688,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/","name":"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=","datePublished":"2022-10-27T11:56:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTk5OCM1MjIzNTEzIzIxOTI5NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701677"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701677\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}